stage IVB salivary gland cancer
Showing 1 - 25 of >10,000
Metastatic Salivary Gland Carcinoma, Recurrent Salivary Gland Carcinoma, Stage IV Major Salivary Gland Cancer AJCC v8 Trial in
Recruiting
- Metastatic Salivary Gland Carcinoma
- +5 more
- Pembrolizumab
- Pemetrexed Disodium
-
Scottsdale, Arizona
- +2 more
Mar 15, 2022
Head and Neck Squamous Cell Carcinoma, Recurrent Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma, Recurrent Nasopharynx
Active, not recruiting
- Head and Neck Squamous Cell Carcinoma
- +14 more
- Laboratory Biomarker Analysis
- +2 more
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Jan 11, 2022
Stage IV Head and Neck Cancer or Stage III-IV Non-small Cell
Active, not recruiting
- Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma
- +29 more
- Cytology specimen
- Laboratory biomarker analysis
-
Philadelphia, PennsylvaniaThomas Jefferson University
Aug 31, 2021
Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With
Completed
- Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma
- +35 more
- PI3K inhibitor BKM120
- cetuximab
-
Chicago, IllinoisUniversity of Chicago Comprehensive Cancer Center
Sep 14, 2021
Caregiver, Malignant Head and Neck Tumor, Paranasal Sinus Squamous Cell Carcinoma Trial in Winston-Salem (Communication
Completed
- Caregiver
- +37 more
- Communication Intervention
- +5 more
-
Winston-Salem, North CarolinaComprehensive Cancer Center of Wake Forest University
Dec 14, 2022
GENE EXPRESSION PROFILING IN A VALIDATION COHORT OF LOCALLY
Not yet recruiting
- Salivary Gland Cancer
- Observation
- (no location specified)
Oct 13, 2023
Gland, Salivary Gland Cancers Trial in Houston (Sacituzumab Govitecan)
Not yet recruiting
- Gland
- Salivary Gland Cancers
- Sacituzumab Govitecan
-
Houston, TexasM D Anderson Cancer Center
May 22, 2023
Metastatic Salivary Gland Carcinoma, Recurrent Salivary Gland Carcinoma, Stage III Major Salivary Gland Cancer AJCC v8 Trial
Recruiting
- Metastatic Salivary Gland Carcinoma
- +4 more
- Docetaxel
- +3 more
-
New York, New YorkMemorial Sloane Kettering Cancer Center
Jan 11, 2023
Salivary Gland Cancer, Salivary Duct Carcinoma, Adenoid Cystic Carcinoma Trial in Nijmegen (Lutetium-177-PSMA-I&T)
Recruiting
- Salivary Gland Cancer
- +2 more
-
Nijmegen, Gelderland, NetherlandsRadboudumc
Oct 27, 2022
Salivary Gland Carcinoma Trial in United States (Goserelin Acetate, Pembrolizumab)
Recruiting
- Salivary Gland Carcinoma
- Goserelin Acetate
- Pembrolizumab
-
Chicago, Illinois
- +6 more
Sep 22, 2022
PSMA-PET Imaging of Salivary Gland Tumours and Other Rare
Recruiting
- Salivary Gland Tumor
- Rare Malignant Neoplasm
- 68-Ga PSMA PET scan
-
Singapore, SingaporeNational Cancer Centre Singapore
Oct 11, 2022
Locally Advanced or Recurrent/Metastatic Salivary Gland Carcinoma, Neoadjuvant or Conversion Therapy, Precision Therapy Trial in
Recruiting
- Locally Advanced or Recurrent/Metastatic Salivary Gland Carcinoma
- +2 more
- Vedolizumab
- +5 more
-
Beijing, Beijing, China
- +1 more
Nov 21, 2023
Salivary Gland Cancer, HER2 Gene Mutation Trial in Boston (Ado-trastuzumab (T) emtansine (T-DM1), Standard of Care Radiotherapy,
Recruiting
- Salivary Gland Cancer
- HER2 Gene Mutation
- Ado-trastuzumab (T) emtansine (T-DM1)
- +2 more
-
Boston, Massachusetts
- +1 more
Jan 2, 2023
Salivary Gland Cancer Trial (vedicitumomab (Edisil, RC48), vedicitumomab in combination with pyrrolizidine, RC48 in combination
Not yet recruiting
- Salivary Gland Cancer
- vedicitumomab (Edisil, RC48)
- +3 more
- (no location specified)
Jun 9, 2023
Locally Advanced Salivary Gland Carcinoma, Metastatic Salivary Gland Carcinoma, Recurrent Salivary Gland Carcinoma Trial
Not yet recruiting
- Locally Advanced Salivary Gland Carcinoma
- +3 more
- Biopsy
- +3 more
- (no location specified)
Jan 10, 2023
Salivary Gland Cancer, Salivary Gland Tumors Trial in Novi Sad (Surgical intervention with or without postoperative adjuvant
Completed
- Salivary Gland Cancer
- Salivary Gland Neoplasms
- Surgical intervention with or without postoperative adjuvant therapy
-
Novi Sad, SerbiaClinic for maxillofacial surgery Clinical center of Vojvodina
May 22, 2022
Columnar Cell Variant Thyroid Gland Papillary Carcinoma, Follicular Variant Thyroid Gland Papillary Carcinoma, Metastatic
Active, not recruiting
- Columnar Cell Variant Thyroid Gland Papillary Carcinoma
- +25 more
- Laboratory Biomarker Analysis
- +3 more
-
Torrance, California
- +6 more
Jan 12, 2023
Xerostomia Due to Hyposecretion of Salivary Gland Trial in Cairo (Chamomile, Saline mouthwash)
Completed
- Xerostomia Due to Hyposecretion of Salivary Gland
- Chamomile
- Saline mouthwash
-
Cairo, EgyptAin Shams University
Nov 1, 2023
Recurrent Oral Cavity Adenoid Cystic Carcinoma, Recurrent Salivary Gland Carcinoma, Salivary Gland Adenoid Cystic Carcinoma
Completed
- Recurrent Oral Cavity Adenoid Cystic Carcinoma
- +11 more
- Laboratory Biomarker Analysis
- Vorinostat
-
Duarte, California
- +11 more
Jul 14, 2020
Salivary Gland Carcinoma, Adenoid Cystic Carcinoma, Salivary Gland Cancer Trial in Boston (9-ING-41, Carboplatin)
Withdrawn
- Salivary Gland Carcinoma
- +3 more
-
Boston, MassachusettsDana-Farber Cancer Institute
Feb 5, 2022
Head Neck Cancer Trial in Groningen (Submandibular Gland Stem Cell Transplantation)
Recruiting
- Head and Neck Cancer
- Submandibular Gland Stem Cell Transplantation
-
Groningen, NetherlandsUMCG
May 24, 2022
Adenoid Cystic Carcinoma, Salivary Gland Cancer Trial in United States (Lenvatinib, Pembrolizumab)
Recruiting
- Adenoid Cystic Carcinoma
- Salivary Gland Cancer
-
Miami, Florida
- +7 more
Oct 26, 2022
Malignant Salivary Gland Cancer, Salivary Gland Cancer Trial in Tampa, Chicago, Ann Arbor (APG-115, Carboplatin)
Recruiting
- Malignant Salivary Gland Cancer
- Salivary Gland Cancer
-
Tampa, Florida
- +2 more
Feb 10, 2022
Thyroid Cancer, Salivary Gland Cancer Trial in Chicago (Pembrolizumab, Docetaxel)
Recruiting
- Thyroid Cancer
- Salivary Gland Cancer
-
Chicago, IllinoisUniversity of Chicago Comprehensive Cancer Center
Apr 13, 2022